Gunderson Dettmer client Orbis Biosciences, a pharmaceutical company that integrates technology to create products that are safer and more effective than current treatment options, was acquired by Adare Pharmaceuticals.

In the announcement of the transaction president and CEO of Orbis Biosciences Maria Flynn said, “The acquisition by Adare will globalize the reach of our technologies and services. Orbis’s focus on precision delivery solutions has enabled us to develop expertise in novel extended-release and pulsatile-release formulations and to collaborate with great partners. We are pleased to join Adare, an industry leader in drug formulation development and manufacturing.”

The Gunderson Dettmer deal team included Colman Lynch, Valdemar Washington, Caroline Ceriello and Piper Miles-Coccaro.